selected publications
- Revolutionizing prostate cancer treatment: PSMA-targeted therapy in modern therapeutics. Revista espanola de medicina nuclear e imagen molecular. 2025 Review GET IT
-
Advances in PSMA-Targeted Radionuclide Therapeutics.
Current treatment options in oncology.
2025
Review
GET IT
Times cited: 1 -
Antibody-drug conjugates in urothelial carcinoma: current status and future.
Current opinion in urology.
2025
Review
GET IT
Times cited: 1 -
Quantification of collagen content and stromal cellularity within reactive stroma is predictive of prostate cancer biochemical recurrence and specific death.
Human pathology.
2023
Academic Article
GET IT
Times cited: 1 -
Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis.
Human pathology.
2022
Academic Article
GET IT
Times cited: 16 -
Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
European urology.
2019
Academic Article
GET IT
Times cited: 41